Q1 Earnings Forecast for XENE Issued By HC Wainwright

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – HC Wainwright issued their Q1 2025 EPS estimates for shares of Xenon Pharmaceuticals in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst D. Tsao expects that the biopharmaceutical company will post earnings of ($0.88) per share for the quarter. HC Wainwright has a “Buy” rating and a $53.00 price target on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Xenon Pharmaceuticals’ Q2 2025 earnings at ($0.89) EPS, Q3 2025 earnings at ($0.90) EPS and Q4 2025 earnings at ($0.91) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.01. During the same period in the previous year, the company earned ($0.73) EPS.

A number of other brokerages have also weighed in on XENE. Needham & Company LLC restated a “buy” rating and set a $60.00 target price on shares of Xenon Pharmaceuticals in a research report on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, September 3rd. Wedbush lowered their price target on shares of Xenon Pharmaceuticals from $50.00 to $49.00 and set an “outperform” rating for the company in a report on Friday, August 9th. Raymond James reissued an “outperform” rating and issued a $50.00 target price on shares of Xenon Pharmaceuticals in a research note on Thursday, October 10th. Finally, William Blair upgraded Xenon Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Eleven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $57.45.

Xenon Pharmaceuticals Trading Down 4.6 %

Shares of XENE opened at $39.83 on Friday. Xenon Pharmaceuticals has a 12-month low of $28.10 and a 12-month high of $50.99. The company has a market capitalization of $3.04 billion, a PE ratio of -14.12 and a beta of 1.25. The business’s 50 day moving average is $41.18 and its 200 day moving average is $40.36.

Hedge Funds Weigh In On Xenon Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Blue Trust Inc. increased its holdings in Xenon Pharmaceuticals by 174.7% during the third quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 641 shares during the period. nVerses Capital LLC bought a new stake in Xenon Pharmaceuticals during the 3rd quarter valued at $102,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Xenon Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 487 shares during the period. Quarry LP raised its position in shares of Xenon Pharmaceuticals by 207.7% in the 2nd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock worth $156,000 after acquiring an additional 2,700 shares in the last quarter. Finally, EntryPoint Capital LLC purchased a new stake in shares of Xenon Pharmaceuticals during the 1st quarter worth $195,000. Institutional investors own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.